Abstract
Epidermal Growth Factor Receptor (EGFR) is still the main target of the Head and Neck Squamous Cell Cancer (HNSCC) because its overexpression has been detected in more than 90% of this type of cancer. This overexpression is usually linked with more aggressive disease, increased resistance to chemotherapy and radiotherapy, increased metastasis, inhibition of apoptosis, promotion of neoplastic angiogenesis, and, finally, poor prognosis and decreased survival. Due to this reason, the main target in the search of new drugs and inhibitors candidates is to downturn this overexpression. Quantitative Structure-Activity Relationship (QSAR) is one of the most widely used approaches while looking for new and more active inhibitors drugs. In this contest, a lot of authors used this technique, combined with others, to find new drugs or enhance the activity of well-known inhibitors. In this paper, on one hand, we will review the most important QSAR approaches developed in the last fifteen years, spacing from classical 1D approaches until more sophisticated 3D; the first paper is dated 2003 while the last one is from 2017. On the other hand, we will present a completely new QSAR approach aimed at the prediction of new EGFR inhibitors drugs. The model presented here has been developed over a dataset consisting of more than 1000 compounds using various molecular descriptors calculated with the DRAGON 7.0© software.
Keywords: Head and Neck Squamous Cell Carcinoma, Epidermal Growth Factor Receptor, Tyrosine Kinase Inhibitors, Drug Design, Quantitative Structure Activity Relationships (QSAR), Classification and Regression Techniques, Machine Learning.
Current Topics in Medicinal Chemistry
Title:Looking for New Inhibitors for the Epidermal Growth Factor Receptor
Volume: 18 Issue: 3
Author(s): Riccardo Concu*M. Natalia D.S. Cordeiro
Affiliation:
- REQUIMTE, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Rua do Campo Alegre, 687, 4169-007 Porto,Portugal
Keywords: Head and Neck Squamous Cell Carcinoma, Epidermal Growth Factor Receptor, Tyrosine Kinase Inhibitors, Drug Design, Quantitative Structure Activity Relationships (QSAR), Classification and Regression Techniques, Machine Learning.
Abstract: Epidermal Growth Factor Receptor (EGFR) is still the main target of the Head and Neck Squamous Cell Cancer (HNSCC) because its overexpression has been detected in more than 90% of this type of cancer. This overexpression is usually linked with more aggressive disease, increased resistance to chemotherapy and radiotherapy, increased metastasis, inhibition of apoptosis, promotion of neoplastic angiogenesis, and, finally, poor prognosis and decreased survival. Due to this reason, the main target in the search of new drugs and inhibitors candidates is to downturn this overexpression. Quantitative Structure-Activity Relationship (QSAR) is one of the most widely used approaches while looking for new and more active inhibitors drugs. In this contest, a lot of authors used this technique, combined with others, to find new drugs or enhance the activity of well-known inhibitors. In this paper, on one hand, we will review the most important QSAR approaches developed in the last fifteen years, spacing from classical 1D approaches until more sophisticated 3D; the first paper is dated 2003 while the last one is from 2017. On the other hand, we will present a completely new QSAR approach aimed at the prediction of new EGFR inhibitors drugs. The model presented here has been developed over a dataset consisting of more than 1000 compounds using various molecular descriptors calculated with the DRAGON 7.0© software.
Export Options
About this article
Cite this article as:
Concu Riccardo *, Cordeiro Natalia D.S. M., Looking for New Inhibitors for the Epidermal Growth Factor Receptor, Current Topics in Medicinal Chemistry 2018; 18 (3) . https://dx.doi.org/10.2174/1568026618666180329123023
DOI https://dx.doi.org/10.2174/1568026618666180329123023 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dual Inhibitors of PI3K/mTOR or mTOR-Selective Inhibitors: Which Way Shall We Go?
Current Medicinal Chemistry Hybrid PET/MRI for In Vivo Imaging of Cancer: Current Clinical Experiences and Recent Advances
Current Medical Imaging Laminin-332-Integrin Interaction: A Target For Cancer Therapy?
Current Medicinal Chemistry Epigenetic Effects of Cadmium in Cancer: Focus on Melanoma
Current Genomics Targeting p53 in Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Alternative Splicing: A Promising Target for Pharmaceutical Inhibition of Pathological Angiogenesis?
Current Pharmaceutical Design Role of Protein Tyrosine Phosphatase in Regulation of Cell Signaling Cascades Affecting Tumor Cell Growth: A Future Perspective as Anti-Cancer Drug Target
Current Pharmaceutical Biotechnology Vitamin D and Cancer Mortality: Systematic Review of Prospective Epidemiological Studies
Anti-Cancer Agents in Medicinal Chemistry Understanding the Monoclonal Antibody Involvement in Targeting the Activation of Tumor Suppressor Genes
Current Topics in Medicinal Chemistry Recent Patents in Oncolytic Virotherapy
Recent Patents on Biotechnology Small Molecular Inhibitors Targeting Chromatin Regulating Proteins for Cancer
Current Protein & Peptide Science Carrier Deformability in Drug Delivery
Current Pharmaceutical Design Nuclear Factor-κB: A Holy Grail in Cancer Prevention and Therapy
Current Signal Transduction Therapy Multicomponent Reactions in Antimitotic Drug Discovery
Current Topics in Medicinal Chemistry Making the Most of Pathological Specimens: Molecular Diagnosis in Formalin-Fixed, Paraffin Embedded Tissue
Current Drug Targets Alkylphospholipids are Signal Transduction Modulators with Potential for Anticancer Therapy
Anti-Cancer Agents in Medicinal Chemistry The Role of Notch Signaling Pathway in Epithelial-Mesenchymal Transition (EMT) During Development and Tumor Aggressiveness
Current Drug Targets From TGF-β to Cancer Therapy
Current Drug Targets Control of Copper Status for Cancer Therapy
Current Cancer Drug Targets Novel Molecular-Targeted Therapeutics for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry